文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

血必净注射液对脓毒症患者急性胃肠损伤的影响:一项回顾性队列研究

[Effect of Xuebijing injection on acute gastrointestinal injury in patients with sepsis: a retrospective cohort study].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2024-01-01
一句话结论在非胃肠来源脓毒症患者中,使用血必净注射液者急性胃肠损伤发生率50.87%低于未使用者的70.83%,但28天死亡率无显著差异。

该回顾性队列研究纳入秦皇岛市第一医院重症医学科2021年5月1日至2023年10月30日收治的129例非胃肠来源脓毒症患者,按是否使用血必净注射液分为血必净组57例和非血必净组72例。结果显示血必净组急性胃肠损伤(AGI)发生率显著低于非血必净组[50.87%(29/57)vs. 70.83%(51/72),P<0.05],28天死亡率略低但无统计学差异[24.56%(14/57)vs. 30.56%(22/72),P>0.05]。血必净组入院7天C反应蛋白(CRP)和降钙素原(PCT)下降幅度大于非血必净组,差异有统计学意义。多因素Logistic回归显示,使用抑酸剂、使用镇痛镇静剂和泌尿系感染是脓毒症合并AGI的独立危险因素,而使用血必净注射液是保护因素(OR=0.315,95%CI 0.137-0.726,P=0.007)。

要点

  • 血必净组AGI发生率50.87%(29/57)显著低于非血必净组70.83%(51/72),P<0.05。
  • 血必净组28天死亡率24.56%(14/57)略低于非血必净组30.56%(22/72),但P>0.05。
  • 血必净组7天CRP下降幅度(mg/L)47.12±67.34大于非血必净组7.76±111.03,PCT下降幅度(μg/L)14.08(-1.22,50.40)大于2.94(-1.27,14.80),均P<0.05。
  • 使用抑酸剂(OR=2.450,95%CI 1.021-5.883,P=0.045)、使用镇痛镇静剂(OR=2.521,95%CI 1.074-5.918,P=0.034)和泌尿系感染(OR=4.011,95%CI 1.085-14.831,P=0.037)是脓毒症合并AGI的独立危险因素。
  • 使用血必净注射液是脓毒症合并AGI的保护因素(OR=0.315,95%CI 0.137-0.726,P=0.007)。

适用人群与场景

  • 2021年5月1日至2023年10月30日入住秦皇岛市第一医院重症医学科的非胃肠来源脓毒症患者。
  • 共纳入129例,其中血必净组57例、非血必净组72例;合并AGI组80例、未合并AGI组49例。

研究设计与关键结果

  • 研究类型:回顾性队列研究;单中心(秦皇岛市第一医院);样本量129例非胃肠来源脓毒症患者。
  • 分组:按是否使用血必净注射液分为血必净组57例和非血必净组72例;按是否合并AGI分为合并AGI组80例和未合并AGI组49例。
  • 主要终点:血必净组AGI发生率显著低于非血必净组[50.87%(29/57)vs. 70.83%(51/72),P<0.05]。
  • 28天死亡率:血必净组24.56%(14/57)略低于非血必净组30.56%(22/72),P>0.05。
  • 7天CRP下降幅度(mg/L):血必净组47.12±67.34大于非血必净组7.76±111.03,P<0.05。
  • 7天PCT下降幅度(μg/L):血必净组14.08(-1.22,50.40)大于非血必净组2.94(-1.27,14.80),P<0.05。
  • 单因素分析显示,使用抑酸剂、使用镇痛镇静剂、未使用血必净注射液、肺部感染和泌尿系感染是脓毒症患者发生AGI的危险因素。
  • 多因素Logistic回归:使用抑酸剂(OR=2.450,95%CI 1.021-5.883,P=0.045)、使用镇痛镇静剂(OR=2.521,95%CI 1.074-5.918,P=0.034)和泌尿系感染(OR=4.011,95%CI 1.085-14.831,P=0.037)是独立危险因素;使用血必净注射液是保护因素(OR=0.315,95%CI 0.137-0.726,P=0.007)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,血必净注射液可降低非胃肠来源脓毒症患者的AGI发生率。
  • 作者认为,使用抑酸剂、镇痛镇静剂和泌尿系感染是脓毒症合并AGI的独立危险因素,使用血必净注射液是保护因素。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effect of Xuebijing injection on sepsis combined with acute gastrointestinal injury (AGI), and analyze the risk factors of sepsis combined with AGI.

METHODS: A retrospective cohort study was conducted. Patients with non-gastrointestinal origin admitted to the department of intensive care medicine of the First Hospital of Qinhuangdao from May 1, 2021 to October 30, 2023 were enrolled. The baseline data, source of sepsis infection, vital signs, acute physiology and chronic health evaluation II (APACHE II), sequential organ failure assessment (SOFA), laboratory tests, comorbidities, interventions during treatment, and the 28-day prognosis were collected. The patients were divided into Xuebijing group and non-Xuebijing group according to whether Xuebijing injection was used or not. According to whether AGI was merged or not, patients were divided into merged AGI group and non-merged AGI group. The main observational indexes were the difference in the incidence of AGI between the Xuebijing group and non-Xuebijing group and the difference in the magnitude of the decline in procalcitonin (PCT), C-reactive protein (CRP), and white blood cell count (WBC) at 7 days after admission, and the difference in the 28-day morbidity and mortality. Risk factors for AGI in septic patients were explored by univariate analysis, and statistically significant indicators were screened and included in binary Logistic regression analysis to determine independent risk factors.

RESULTS: A total of 129 patients with sepsis of non-gastrointestinal origin were enrolled, including 57 patients in the Xuebijing group and 72 patients in the non-Xuebijing group. Among 129 patients, 80 patients in the merged AGI group and 49 patients in the non-merged AGI group. There were no statistically significant differences between Xuebijing group and non-Xuebijing group in gender, age, body mass index (BMI), underlying disease, source of infection, vital sign, APACHE II score, SOFA score, and clinical intervention, and there were no statistically significant differences in laboratory tests except for aspartate aminotransferase (AST) and blood urea nitrogen (BUN). The incidence of AGI was significantly lower in the Xuebijing group than that in the non-Xuebijing group [50.87% (29/57) vs. 70.83% (51/72), P < 0.05], and the 28-day mortality was slightly lower than that in the non-Xuebijing group [24.56% (14/57) vs. 30.56% (22/72), P > 0.05]. In the Xuebijing group, the decreases in CRP, PCT and WBC at 7 days after admission were greater than those in the non-Xuebijing group, with statistically significant differences in the decreases of CRP and PCT [CRP (mg/L): 47.12±67.34 vs. 7.76±111.03, PCT (μg/L): 14.08 (-1.22, 50.40) vs. 2.94 (-1.27, 14.80), all P < 0.05]. Univariate analysis showed that the use of acid suppressants, the use of analgesic sedation, the non-use of Xuebijing injections, pulmonary infections, and urinary tract infections were the risk factors for the development of AGI in patients with sepsis. Binary Logistic regression analysis further showed that the use of acid suppressants [odds ratio (OR) = 2.450, 95% confidence interval (95%CI) was 1.021-5.883, P = 0.045], use of analgesic sedatives (OR = 2.521, 95%CI was 1.074-5.918, P = 0.034), and urinary tract infection (OR = 4.011, 95%CI was 1.085-14.831, P = 0.037) were independent risk factors for sepsis combined with AGI, in which the use of Xuebijing injection was a protective factor (OR = 0.315, 95%CI was 0.137-0.726, P = 0.007).

CONCLUSIONS: Xuebijing injection reduced the incidence of AGI in patients with non-gastrointestinal sepsis. PCT and CRP decreased more markedly than in patients who did not use Xuebijing injection. The use of acid-suppressing agents, analgesic and sedative agents, and urinary tract infections were independent risk factors for sepsis in combination with AGI, while the use of Xuebijing injection is a protective factor.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zuo Z, Pei L, Zhang Y, et al. [Effect of Xuebijing injection on acute gastrointestinal injury in patients with sepsis: a retrospective cohort study]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39380515. doi:10.3760/cma.j.cn121430-20240430-00395

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。